Oligodendrocytes (OLs) are glial cells of the central nervous system, which produce myelin. Cultured OLs provide immense therapeutic opportunities for treating a variety of neurological conditions. One of the most promising sources for such therapies is human embryonic stem cells (ESCs) as well as providing a model to study human OL development. For these purposes, an investigation of proteome level changes is critical for understanding the process of OL differentiation. In this report, an iTRAQ-based quantitative proteomic approach was used to study multiple steps during OL differentiation including neural progenitor cells, glial progenitor cells and oligodendrocyte progenitor cells (OPCs) compared to undifferentiated ESCs. Using a 1% false discovery rate cutoff, $3145 proteins were quantitated and several demonstrated progressive stage-specific expression. Proteins such as transferrin, neural cell adhesion molecule 1, apolipoprotein E and wingless-related MMTV integration site 5A showed increased expression from the neural progenitor cell to the OPC stage. Several proteins that have demonstrated evidence or been suspected in OL maturation were also found upregulated in OPCs including fatty acid-binding protein 4, THBS1, bone morphogenetic protein 1, CRYAB, transferrin, tenascin C, COL3A1, TGFBI and EPB41L3. Thus, by providing the first extensive proteomic profiling of human ESC differentiation into OPCs, this study provides many novel proteins that are potentially involved in OL development.
Introduction
Oligodendrocytes (OLs) are central nervous system (CNS) glial cells that produce myelin, a multilamellar macromolecule that provides insulation to neuronal axons. Cultured OL lineage cells provide immense therapeutic opportunities for treating a variety of neurological conditions involving axonal demyelination. One of the most promising sources for such therapies is human embryonic stem cells (ESCs), which provide seemingly unlimited proliferation in vitro and are capable of differentiating into cells of all three germ layers. Moreover, ESCs are receptive to genetic manipulation and can therefore be optimized towards a particular therapeutic function. The use of human ESC-derived oligodendrocyte progenitor cells (OPCs) in rodent models of spinal cord injury and multiple sclerosis has been previously documented in the literature [1, 2] . Notably, the transplantation of human ESC-derived OPCs into the spinal cord of contused rats has been shown to promote partial recovery, which has led to the first Food and Drug Administration-approved human clinical trial involving cells derived from human ESCs.
The process of differentiation of pluripotent human ESCs is driven by an alteration of the gene expression program, which ultimately leads to formation of specific cell types. Identification of key factors involved in OPC-specific integration, multiplication and myelination can unveil new strategies for the treatment of a variety of afflictions affected by demyelination. Currently, known regulators of OL development include a multitude of signaling molecules, transcription factors and key metabolic pathways, which have been shown to control OL fate, proliferation, migration and survival [3, 4] . These molecules have been identified through a variety of methods that include in vitro culturing of OPCs with or without the presence of neurons [5] , knockout rodent or chick electroporation studies, and by tissue characterization from patients with OL-affiliated diseases. Importantly, in vitro studies have revealed that cultured OLs produce myelin-associated lipids and proteins in a developmental timetable similar to that seen in vivo as well as demonstrating their ability to produce myelin-like sheaths. Using these approaches, a number of growth factors have been discovered, which promote OPC migration, survival and proliferation including platelet-derived growth factor (PDGF) [6, 7] , fibroblast growth factor (FGF-2) [8, 9] and insulin-like growth factor-I [10] . In contrast to factors that support OPC proliferation, the thyroid hormone triiodothyronine (T3) [11] , neuregulin-1 (NRG1) [12] and transforming growth factor-b (TGF-b1) were found to promote OL differentiation [13] along with FGF-2 when exposed to astrocytes [14] . The inductions of several transcription factors are also required for the maturation of post-mitotic OLs. These include oligodendrocyte transcription factor 1 and 2 (OLIG1, OLIG2), achaete-scute complex homolog 1 (ASCL1), NK2 homeobox 2 (NKX2.2), SRY (sex determining region Y)-box 10 (SOX10), Yin-Yang 1 transcription factor (YY1), myelin gene regulatory factor (MRF) and transcription factor 4 (TCF4) [15] [16] [17] [18] .
Despite the identification of several factors that appear to affect OPC proliferation and differentiation, little is known regarding factors regulating myelination or that initiate this process. While DNA microarray-based experiments have been carried out to identify such molecules, determining the protein expression using a quantitative proteomics approach is the most direct way to identify proteins that are specific to OL differentiation. To this end, we employed a high-throughput quantitative proteomics approach to systematically identify proteomic changes specific to OPC functions. We have previously successfully employed quantitative proteomic approaches to understand the differentiation of human ESCs into neurons and astrocytes [19] . Nanoflow LC combined with high-resolution Fourier transform MS methods allows for quantification of changes in low-abundance cellular proteins. In this report, using state-of-the-art MS analysis, expression profile analysis we have identified and quantified 3145 proteins at key stages of OL differentiation from human ESCs. In addition to generating a comprehensive proteomics database of OPC differentiation, the main objectives of this study were to characterize the progressive stage-specific expression of proteins with known or suspected roles leading to OL maturation and/or myelination and identify novel markers of various stages of OL development including neural progenitor cells (NPCs), glial progenitor cells (GPCs) and OPCs, utilizing a human ESC model of OL differentiation. Of significance, this approach characterizes intermediate time points during differentiation, including GPCs, which are not described in any other global expression profiling studies of the OL lineage.
Materials and methods

Cell culture
H1 (WA01) human ESCs were purchased from WiCell (Madison, WI) and expanded on irradiated mouse embryonic fibroblasts in ESC growth media, consisting of DMEM/ F12, 20% KnockOut serum (Invitrogen), 2 mM glutamax, 2 mM nonessential amino acids and 3.5 mL b-mercaptoethanol supplemented with basic FGF-2. Prior to differentiation, ESCs were dispersed using 0.05% trypsin/EDTA and plated on matrigel (BD Bioscience) for 5 days with feeder-conditioned media. Cells were then differentiated These are not the final page numbers into embryoid bodies [20] , NPCs, GPCs and OPCs, according to previously published protocols [21, 22] .
Briefly, neural differentiation of ESCs was initiated via embryoid body (EB) suspensions with N2B27 medium supplemented with 200 ng/mL noggin, 20 ng/mL FGF-2 and 20 ng/mL FGF-4 (R&D Systems). Neural EBs were grown for 15 days and then plated onto matrigel and grown in N2B27 media supplemented with 20 ng/mL FGF-2 for 5 days to produce nestin1/A2B51NPC, capable of deriving cells with neuronal and glial fates. Next, 20 ng/mL Epidermal growth factor (EGF) (PeproTech) was added to produce Platelet-derived growth factor receptor (PDGFR)-a1/Olig1 1GPC, which can differentiate into either astrocytes or OLs. To promote differentiation into OPCs, the medium was supplemented with 20 ng/mL PDGF-AA (R&D Systems). After 25 days, OPCs were identified by O1, O4, GalC and CNPase expression. Samples for proteomic analysis were isolated from four distinct cell stages: ESC, NPC, GPC and OPC. For these stages, immunocytochemical (ICC) analysis was performed on co-cultures to confirm 495% purity in the expression of markers discussed above.
ICC analysis
Immunocytochemistry was carried out on EBs, NPCs, GPCs and OPCs with primary antibodies listed in Supporting Information Table 1 using standard protocols and fluorescent secondary antibodies (Millipore). The cells were frozen in Octamer binding transcription factor 4 (OCT4) freezing compound (TissueTek), sliced into 5 mm sections and positioned on slides (ProbeOn Plus, Fisher Scientific). DAPI was used for nucleus staining to determine the percentage of immunopositive cells.
Cell lysates, in-solution digestion and iTRAQ labeling
Four different cell stages generated in duplicate (in total of eight cell culture plates) were pooled and selected for proteomic analysis (Fig. 1) [23] . Briefly, 80 mg proteins from each cell type was reduced using 2 mL of tris(2-carboxyethyl) phosphine at 601C for 1 h and cysteine residues were alkylated with 1 mL of methyl methanethiosulfonate for 10 min at room temperature. The samples were diluted in 50 mM triethylamonium bicarbonate to dilute the SDS concentration to 0.02%. The samples were then digested using sequencing grade trypsin (Promega) (1:20) for 12 h at 371C. The volume of digestion mixture was reduced by vacuum drying and peptides from each sample in a final volume of 35 mL was incubated with one of the four iTRAQ reagents diluted in 70 mL of absolute ethanol (200 proof) at room temperature. The peptides from ESCs, NPCs, GPCs and OPCs were labeled using iTRAQ reagents containing 114, 115, 116 and 117 reporter ions, respectively. After 2 h, 100 mL water was added to each iTRAQ labeling reaction mixture and the samples were vacuum dried to $40 mL to remove excess of triethyl ammonium bicarbonate and ethanol. The samples were subsequently combined and diluted to 1 mL in 5 mM potassium phosphate buffer (pH 2.7) containing 30% acetonitrile (Solvent A). The pH of the sample was adjusted to 2.7 using 100 mM phosphoric acid. The iTRAQ labeled peptides were fractionated using strong cation exchange (SCX) chromatography using polysulfoethyl A column (PolyLC, Columbia, MD) (300 Å , 5 mm, 100 Â 2.1 mm) [24] on an Agilent 1100 HPLC system consisting of a binary pump, external sample injector, UV detector and a fraction collector. Fractionation was carried out for a period of 45 min using a linear gradient of increasing salt concentration of up to 350 mM KCl in solvent A. The fractions were pooled to generate 14 fractions and dried in vacuum dryer. The samples were reconstituted in 40 mL of 0.1% trifluoroacetic acid and desalted using homemade C 18 (3 M Empore high-performance extraction disks) stage-tips in 200 mL pipette tips. The samples were split into two sets, one was analyzed on linear trap quadrupole (LTQ)-Orbitrap XL and other was analyzed on LTQ-Orbitrap Velos.
LC-MS/MS
Nanoflow electrospray ionization LC-MS/MS analysis of the first set of iTRAQ labeled samples was carried out on an LTQ Orbitrap XL (Thermo Scientific) interfaced with reversed phase system controlled by Eksigent nano-LC and Agilent 1100 microwell plate autosampler. The second set was analyzed as a technical replicate using LTQ Orbitrap Velos (Thermo Scientific) mass spectrometer. The desalted SCX fractions were rapidly enriched (5 mL/min) on a trap column (75 mm Â 2 cm, Magic C 18 AQ Michrom Bioresources, 5 mm, 100 Å ) and separated on an analytical column (75 mm Â 10 cm, Magic C 18 AQ Michrom Bioresources, 5 mm, 100 Å ) with a nanoflow solvent delivery. The MS and MS/MS data were acquired at a resolution of 60 000 at m/z 400 and 7500 at m/z 400, respectively. For each cycle of data-dependent analysis, ten and 20 most abundant peptides were selected for MS/MS analysis in LTQ Orbitrap XL (normalized collision energy 37%) and LTQ Orbitrap Velos (normalized collision energy 40%), respectively. Higher collision dissociation mode was used for MS/MS scans. Two-stepped collision energy with a width of 6% was used to cover the best fragmentation event in which two
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normalized collision energies around the set CEs were applied to fragment the peptides.
MS data analysis
The MS data were processed using Proteome Discoverer (Version 1.2.0.208) software (Thermo Scientific) workflow. The Proteome Discoverer workflow consisted of spectrum selector and reporter ion quantifier including MASCOT and Sequest search nodes ( Fig. 1) . MS/MS spectral data were also processed using extract feature of Proteome discoverer under MASCOT search component of the workflow. For both nodes, the same search parameters were selected, which include iTRAQ label at tyrosine, oxidation of methionine, deamidation at NQ as variable modifications. iTRAQ label at N-terminus and lysine, methylthio label at cysteine were used as fixed modifications. The MS data were searched against NCBI RefSeq 40 human protein database containing 31 811 sequences. Using proteome discoverer workflow, the data from MASCOT and Sequest search nodes were merged to obtain average quantitation values from replicates. False discovery rate (FDR) for peptide search is a statistical value that determines the number of false identifications among all identifications. Proteome Discoverer calculates the percentage of false identifications using a separate decoy database (reverse database) that contains the reversed sequences of the protein entries. An FDR threshold of 1% was used in this study. The software counts the number of matches from both searches and calculates the FDR by counting only the top match per spectrum assuming that only one peptide can be the correct match. The score thresholds are adjusted to obtain 1% reversed hits compared to forward hits. MASCOT significant threshold based on peptide score was used as filter settings for FDR calculation in MASCOT searches and Xcorr versus charge state for filter settings in Sequest searches. Precursor and reporter ion window tolerance were fixed at 20 ppm and 0.05 Da, respectively. The criteria specified for generation of peak lists include signal to noise ratio of 1.5 and inclusion of precursor mass range of 600-8000 Da. Proteome Discoverer software performs automated statistical analysis of the results and uses unique peptides to calculate accurate relative protein quantitation. The peptide and protein data were extracted using high peptide confidence and top one peptide rank filters. FDR was calculated by enabling the peptide sequence analysis using decoy database. The average ratio and percentage variability was used for protein quantitation wherever multiple peptides were identified for a protein.
Data analysis
Technical and biological replicates were used for MS analysis and ICC analysis of differentiation, respectively. The proteins derived from search results were filtered by using a criterion of 42.0-fold change relative to the undifferentiated ESCs. Proteins that did not exhibit this cutoff for at least one stage were removed from the analysis. DAVID (database for annotation, visualization and integrated discovery) analysis tool was used to categorize proteins from the data set into functional groups and cellular localizations [25, 26] . Differentially expressed proteins were ranked to produce lists of the top 50 upregulated proteins at each stage of differentiation (NPCs, GPCs and OPCs). To identify upregulated proteins associated with myelination, a custom algorithm was developed within MATLAB (Mathworks, Natick, MA) to conduct an automated Pubmed literature search for each protein along with the keyword ''myelin''. The algorithm returned the number of ''hits'' for each protein, and those returning at least one result were manually evaluated for known or predicted roles in Figure 1 . Outline of the 4-plex iTRAQ-based quantitative proteomic strategy. iTRAQ labeling was carried out using lysates from ESCs, NPCs, GPCs and OPCs. Samples were digested using trypsin and labeled using iTRAQ reagents 114, 115, 116 and 117 with peptides from ESCs, NPCs, GPCs and OPCs, respectively. After labeling, peptides from all four samples were combined and fractionated by SCX chromatography. Each fraction was then analyzed by LC-MS/MS on an LTQ Orbitrap mass spectrometers. The data were analyzed using Proteome Discoverer software.
myelination. To identify potential novel markers of NPCs, GPCs and OPCs, proteins were selected, which demonstrated significant upregulation (42.0-fold change) in only one of these stages and relatively flat expression (o1.0-fold change) across all other stages.
Results
ESC differentiation into OL lineage cells
The differentiation protocol for the generation of NPCs, GPCs and OPCs from human ESCs is shown in Supporting Information Fig. 1A [20] [21] [22] [23] [24] [25] [26] . OPCs also developed multiple filopodial extensions. OPC samples used for proteomic analysis continued to proliferate in culture and did not express myelin basic protein, which is the most common marker of mature OLs. Overall, among 3140 proteins, only 80 proteins including OCT4 and SP3 were excluded from quantitation due to the poor intensity of reporter ions. Nearly 7.4 % of the proteins showed more than twofold upregulation and 6.5% of the proteins showed downregulation in OPCs when compared to ESCs. Figure 3A shows graphical distribution of iTRAQ ratios of all the quantitated proteins and differential expression of a small subset of proteins from OPCs. The majority of proteins (86%) showed no significant change in abundance levels. Individually, NPCs, GPCs and OPCs showed 5.2, 3.7 and 7.4% upregulated proteins when compared to ESCs, respectively. Similarly, NPCs, GPCs and OPCs showed 2.9, 3.5 and 6.5% downregulated proteins when compared to ESCs, respectively. Samples used for iTRAQ experiments were normalized by averaging iTRAQ fold changes of peptides from actin a2 for each stage. Results include $1650 peptide-spectrum matches from 22 peptides (Fig. 3B ).
LC-MS/MS analysis of iTRAQ-labeled peptides
iTRAQ reporter ion spectra of representative peptides from proteins with different expression levels in ESCs, NPCs, GPCs and
Differentially expressed proteins
Proteins with more than twofold increase in abundance as compared to ES cells were classified as differentially upregulated, and those with abundance ratios of 0.5-fold or less as compared to ES cells were classified as differentially downregulated. Supporting Information Table 4 shows the GPC stage showed 113 upregulated proteins and 107 downregulated proteins. At GPC stage krueppel-like factor 16 (KLF16) was highly expressed (412-fold increase) when compared to ESCs. Cells at the OPC stage contained the greatest differential expression relative to ESCs, with 223 upregulated proteins and 198 downregulated proteins. In both GPCs and OPCs, prenylcysteine oxidase-like (PCYOX1L) matrix metalloproteinase 9 (MMP9), COP9 constitutive photomorphogenic homolog subunit 2 isoform 1 (COPS2) showed more than 12-fold upregulation when compared to ESCs. The most highly expressed protein at GPC stage includes high mobility group protein HMGI-C isoform a, b-crystallin B3, hypothetical protein encoded by C6orf211, a 2 type IV collagen (with a fold-change of 415). Therefore, this data set is the first comprehensive report of the earliest differences in protein expression seen during glial differentiation from ESCs.
Several pluripotency markers including PODXL, LIN28A, LIN28B, TRIM28, LEFTY2 showed decreased expression levels during differentiation (r0.5-fold in at least one stage, Supporting Information Table 5 ). Due to increased sensitivity and high-resolution MS, we were able to identify many transcription factors expressed in ESCs. The levels of many of the proteins involved in transcription regulation (SP1, CHAF1B, DNMT3A, EHMT1, JARID2, MYBBP1A, NFXL1, ORC2, PAWR, SQSTM1 and TIAL1) were found to be decreased during ESC differentiation (r0.5-fold in at least one stage, Supporting Information Table 5 ).
Functional analysis of the protein data set using database for annotation, visualization and integrated discovery [27] tool revealed differential regulation of important classes of proteins in ESCs, NPCs, GPCs and OPCs. Table 1 categorizes proteins predominately expressed at each stage, which are associated with transcriptional regulation, plasma membrane proteins, proteins implicated in cell differentiation, cell signaling, and cell adhesion.
Differentially expressed proteins in OPCs
As expected, cells at the OPC stage contained the greatest number (26) of differentially expressed proteins with known or suggested roles in myelination. A large majority of these proteins (88%) demonstrated the greatest upregulation at the OPC stage, including neural cell adhesion molecule 1 (NCAM1), APOE, tenascin C (TNC), vimentin (VIM), wingless-related MMTV integration site 5A (WNT5A), and heat shock 27 kDa protein 1 among several others. NCAM1 is a cell adhesion molecule found in both neurons and OLs, which has been suspected to be involved in axon-OL signaling during myelination. Upregulation of NCAM1 in cultured OPCs was found to promote radial process outgrowth [28] . Our results show that protein levels increased as ES cells differentiated into OPCs, concomitant with increased outgrowth of radial processes. Similarly, brain acid-soluble protein (BASP1) has also been shown to promote neurite outgrowth [29] and in our data increased throughout differentiation, suggesting a role in OL process development. Additionally, a group of crystallins (CRYAA, CRYAB, CRYBA1 and CRYBB) showed significantly higher expression in OPCs compared to other stages (Fig. 2,  panel K) . Recently CRYAB has been shown to specifically accumulate in OLs [30] CRYAB, an inhibitor of inflammation, has been shown to demonstrate anti-apoptotic and neuroprotective roles in the CNS [31] . Finally, APOE also demonstrated progressive increase during OPC differentiation (Fig. 2, panel H) . Myristoylated alanine-rich Ckinase substrate (MARCKS) is an actin filament crosslinking protein, which plays a role in vesicular trafficking to the myelin sheet in mature OLs. The regulation of PI(4,5)P2 by MARCKS has been suggested to play a role in the outgrowth of membranous cellular processes in mature OLs [32] . Previous studies have found that MARCKS mRNA levels increase as OLs mature, suggesting developmental regulation of this protein [33] . However, there is limited information in the literature regarding the protein expression of MARCKS along OL differentiation. Our protein data show progressive upregulation of MARCKS in developing OLs (Fig. 2, panel G) , in agreement with mRNA data. In addition, bone morphogenetic protein 1 (BMP1), which has been shown to play an important role in OL development, demonstrated significant upregulation. Interestingly, reduction of endogenous BMP1 expression in developing glial cells has been shown to reduce maturation of OLs and myelin protein expression, without affecting OPC numbers [34] . These data are Proteomics 2011, 11, 1-14 ALDH3A2  CASP3  RAB3B  CAV1  DNMT3A  ANK3  EZR  CAV1  CDH1  EHMT1  APOA1  KRT5  APOA1  CGN  JARID2  CASP3  DSP  SQSTM1  CLDN6  MYBBP1A  CAV1  KRT2  RRAS2  CXADR  NFXL1  CDH1  SEMA6A  TAB1  DMXL2  ORC2  CLDN6  TUBB2A  UBE2C  DSG2  PAWR  CLDN7  ANK3  SRPK1  DSP  SP1  CXADR  GJA1  METAP2  GJA1  SQSTM1  DMXL2  CDH1  SPINT2  HLA-A  TIAL1  EPCAM  HLA-C  EZR  LCP1  GJA1  OCLN  HLA-A  PKP2  IFITM1  UBAP2  KRT1  VCL  OCLN  PAWR  PODXL  RAB3B  SLC2A1  SLC3A2  SLC7A5  SPINT2  STXBP2  TAGLN2  TNFRSF8  VCL   NPCs CAND1  ACTR2  AMBRA1  ARHGEF2  ARHGAP17  CREB1  AMFR  CD44  ITGA1  ARHGEF2  EP300  CD44  CREB1  MED14  CD44  HMGA2  CTNNA2  CTNNA2  PKN1  COL11A1  HUWE1  EXOC8  DBN1  RHEB  COL3A1  KLF16  GYPC  DPYSL5  RNF14  CTNNA2  MCTS1  ITGA1  GPSM1  SOD1  ITGA1  MED14  NT5E  HUWE1  TGM2  LMO7  RCOR2  PALM  ITGA1  TNIK  SNAP23  RFX3  PON2  SOD1  SYNPO  RNF14  RFTN1  SOX2  RRP8  RHEB  VPS33A  SETD1A  SBF1  SIN3A  SNAP23  SOX2  WHSC1L1  ZSCAN18   GPCs ARHGEF10L  ACTR2  AGRN  AGRN  ARHGAP17  AGRN  AGRN  ATXN10  AXL  CTNNA2  ARID3A  CAPRIN1  CLU  CREB1  LAMA1  BTAF1  CTNNA2  CREB1  KLF16  LAMB1  CAND1  HSPG2  CTNNA2  LAMA1  CAT  NT5E  LAMB1  MAP2K1  CREB1  PON2  MAP2K1  MED14  HMGA2  RFTN1  MMP9  MINK1  HUWE1  RHEB  VPS33A  MMP9  KLF16  SBF1  OXSR1  MCTS1  SLC2A6  RFC4   8 consistent with the increasing endogenous expression of BMP1 in our cultured OPCs, serving to promote later OL maturation. Recent studies in the peripheral nervous system have shown that an APOE-mimetic peptide significantly improved axon elongation, myelin debris clearance and remyelination after crush injury [35] .
Myelination-associated proteins
Next, we compiled an expanded list of proteins shown by previous studies to have either a known or putative role in OL myelinating potential. This was accomplished via a custom script we developed to perform an automated Pubmed literature search for each protein along with the keyword ''myelin''. Proteins that generated one or more hits via this method were manually verified for associated roles in myelination. For this purpose, proteins that showed 42-fold upregulation at the NPC, GPC, and OPC stages relative to the ESC stage were selected for analysis. Figure 4 presents the temporal expression pattern of potential ''myelin-potentiating'' proteins showing differential expression at the NPC stage (panel A), GPC stage (panel B) and OPC stage (panel C). Three of these proteins (synaptosomalassociated protein, 23 kDa (SNAP23), SET-binding factor 1 (SBF1) and TF) were differentially expressed at all three stages. SNAP23, which plays a role in membrane fusion during intracellular trafficking, demonstrated peak expression at the neural progenitor stage and showed high but decreased expression at the GPC and OPC stages. SBF1 was found to decrease as NPCs differentiated into GPCs and then increase upon OPC differentiation. SBF1 is a pseudophosphatase homolog to MTMR13, which has been shown to be associated with demyelination when mutations are present in this gene [36] . Finally, our data for TF show progressively increased expression throughout OL differentiation, aligned with a report by Espinosa-Jeffrey et al. discussing stage-dependent expression of TF (Fig. 2, panel I ) [37] . Interestingly, NPCs and GPCs expressed a similar number of differentially expressed proteins that have been associated with glial development. We found nine such proteins to be significantly upregulated in NPCs and GPCs, which decreased as these cells differentiated into OPCs. Most of these proteins have been associated with astrocyte development. These proteins included CD44 molecule (CD44), superoxide dismutase 1, SNAP23, TRAF2 and NCK interacting kinase (TNIK). Proteins with highest expression at the These are not the final page numbers MED14  SNAP23  RHEB  RCOR2  SPAG9  SPAG9  RFX3  RSF1   OPCs AGRN  ACTR2  AGRN  AGRN  BMP1  ARHGEF10L  AGRN  APOE  APOE  COL12A1  CAND1  AMFR  ATXN10  COL3A1  COL3A1  CAT  BASP1  CRYAA  CRYAB  COL5A1  CRABP2  CCDC8  DBN1  DBNL  COL6A1  FABP4  CRIP2  FN1  GNG2  COL6A3  HMGA2  EPB41L3  ITGA1  GSN  EMILIN1  HUWE1  FN1  MMP9  ITGA1  FN1  KLF16  GNG2  NEFL  KLF16  HSPG2  LBH  GPC6  NEFL  NCAM1  ITGA1  LBH  HSPG2  RELA  OXSR1  LMO7  LMCD1  ITGA1  SFXN1  PRKACA  MFGE8  PBXIP1  MARCKS  TF  PRKAR2A  NCAM1  PBXIP1  MRC2  VPS33A  TGM2  POSTN  RELA  NCAM1  THBS1  SCARB2  SMARCD3  NT5E  WNT5A  TGFBI  TCEA3  PALM  THBS1  WHSC1L1  PON2  TNC  ZNF512B  PON2  RFTN1  SBF1  SCARB2  SLC2A6  SNAP23 Proteomics 2011, 11, 1-14 GPC stage included CLU, AXL receptor tyrosine kinase (AXL), cAMP responsive element binding protein 1 (CREB1) and laminin b 1. CLU levels were found to significantly decrease from the GPC to OPC stages. This protein has been shown to be expressed in astrocytes but not in OLs [38, 39] . Accordingly, the dramatic decrease in expression within our data may be concomitant with the inhibition of astrocyte differentiation and the promotion of OL differentiation.
ICC validation of differentially expressed proteins
Changes in protein levels were validated using ICC staining for several potential regulators of OL maturation. Levels of staining were compared in neural progenitors, glial progenitors and in OL progenitors, which corroborated the proteomic data. WNT5A, MARCKS, APOE, CRYAB and VIM showed increased levels of staining from NPC to OPC while superoxide dismutase 1, SNAP23, and the stem cell marker HMGA1 showed a decline in expression during OPC development (Fig. 5) . Trends similar to the proteomic data were also demonstrated for CLU and TNIK where CLU demonstrated highest expression and TNIK lowest expression in GPCs compared to NPCs and OPCs.
Discussion
Significant discoveries have been made in the past two decades regarding OL development and their roles in disease progression [40] [41] [42] . These studies have included transgenics and knock-out models that have independently demonstrated roles for many growth factors or transcription factors in OL maturation and function (for review see [43] [46] . While these studies provide valuable information and successfully characterized the comprehensive expression of mRNA within these samples, it is difficult to make any firm conclusions concerning the true protein levels. It is well known that posttranscriptional mechanisms such as miRNA regulation commonly account for discrepancies between observed mRNA and protein levels, thus emphasizing the importance of measuring protein levels for a direct indication of ultimate gene expression. Nonetheless, several of the genes identified in these rodent models were also found in our proteomic analyses. For instance, TF, NCAM1, APOE, FABP4, TNC, WNT5A, GDI1 and TGFBI showed consistently increased expression as NPCs differentiated into OPCs. As might be expected from these myelin or OL lineage associated proteins, the majority of these experienced the highest upregulation at the final GPC to OPC stage transition. Interestingly, our previous neuronal proteomics study showed extensive downregulation of APOE in motor neurons and moderate downregulation in astrocytes. Similarly, TNCs showed higher expression in astrocytes than in motor neurons. Together, these expression patterns are consistent with the potential role of TNCs and APOE into glial fate. In contrast, CD44 showed consistent downregulation along differentiation from NPCs to OPCs. CD44 is normally found in astrocytes and microglia and is expressed only during pathological conditions within OLs [47] . Hence, decreased expression of CD44 may be vital for directing neural progenitors into the oligodendroglial fate and away from astrocyte differentiation. In addition, several proteins that have been characterized during OL development demonstrated a unique intermediate pattern of expression in GPCs compared to NPCs and OPCs. For instance, VIM, SBF1, AHNAK, ACAT2, MAP1A, TNIK, insulin-like growth factor BP2, heat shock 27 kDa protein 1 and CRYAB expression decreased from NPCs to GPCs followed by an upregulation in OPCs. Interestingly, these trends were unique for OPC differentiation compared to our previous study of neuronal proteomic profiling, where these proteins demonstrated either a consistent increased or decreased expression during NPC differentiation into HB9 expressing motor neurons.
While the focus of this study was to characterize the developmental stage-specific expression of proteins with known or suspected roles in myelination, another objective was to identify potential novel markers of NPCs, GPCs and OPCs. For example, two proteins were specifically expressed at the NPC stage, including methyl-CpG binding domain protein 3 and activating molecule in beclin-1-regulated autophagy (AMBRA1). Methyl-CpG binding domain protein 3 is involved in histone deacetylation and has been shown to decrease pluripotency by repressing OCT4 in cooperation with CDK2AP1 [48] . As such, its expression in NPCs may be associated with repressing pluripotency and encouraging differentiation. Additionally, the GPC stage resulted in a higher number of potential markers, including pleckstrin homology domain containing, family A member 5 isoform 2 (PLEKHA5), laminin b 1 precursor (LAMB1), laminin a 1 precursor (LAMA1) and nidogen 1 precursor (NID1). NID1 is a glycoprotein that displays increased expression from wk 2 to 10 in the postnatal prefrontal cortex [49] and has been shown to play a role in cell adhesion [50] . Due to its high expression and membrane localization, NID1 may be a useful marker for GPCs. Finally, the OPC stage produced a total of 24 potential markers, including several crystallin proteins (CRYBA1, CRYBB1, CRYBB3, CRYBA4, CRYBA2, CRYAA, CRYAB, CRYGS), galactein-1 (LGALS1), HtrA serine peptidase 1 (HTRA1) and FABP4.
In addition to marker expression, information obtained in these analyses from human cells has potential clinical These are not the final page numbers implications in future translational research involving the OL lineage. For instance, several laboratories have identified changes in the gene and protein expression in schizophrenic [51] and multiple sclerosis patients [40] . While the role of OLs injury in multiple sclerosis is well established [52] numerous lines of evidence implicate the role OL injury in the loss of connectivity associated with schizophrenia [41, 51] . These studies have included comparisons of both transcriptome and proteomic alterations that have identified several OL-related proteins in the progression of disease that were also found here including CNP, TF, QK1 and GSN [41, 51] . Thus, understanding the markers of human OL development will help toward understanding the pathology of OL-associated diseases.
For instance, in OL-associated diseases or injuries, the sensitivity or vulnerability of OLs to oxidative stress and glutamate-related excitotoxicity has been correlated to the underlying pathology (reviewed in [42] ). These studies have focused on the role of proteins involved with apoptosis and glutathione metabolism for OPC and OL survival. This is consistent with our proteomic analyses, which reveal higher levels of SOD and Catalase expression in OPCs compared to ESCs. While the expression of many proteins associated with glutathione metabolism was also detected in our study, their levels of expression did not change during differentiation except for microsomal glutathione S-transferase 1, which revealed decreased expression during OPC differentiation.
In summary, the results from our study show the most comprehensive picture of the oligodendroglial proteome and demonstrates how next generation proteomics can be used to identify low abundant molecules at deep low levels. To name a few such examples, several low-level transcription regulators (LIN28, SOX2, TRIM28, PODXL, POU5F1, STAT3, SALL4), many members of protein complexes (proteasome complex, AP1, AP2 and AP3 protein complexes) and proteins involved in stem cell regulatory network (BMP1, WINT5A) were identified and in many cases quantifiable. By utilizing a quantitative proteomics approach, we were able to rigorously characterize the developmental proteomic expression profile of OPC differentiation from human ES cells. We identified several novel potential markers of NPCs, GPCs and OPCs, in addition to many known and/or putative proteins associated with OL lineage cells. Further exploration of these proteins within the OL lineage is likely to yield novel therapies for diagnosing and treating many OL-associated or demyelinating conditions by enhancing the differentiation of OL lineage cells and ultimately the production of myelin.
All the peptides and corresponding protein data found in this study have been deposited in Human Proteinpedia [53] (www.humanproteinpedia.org, identification number HuPA_00671) to facilitate the dissemination of this data set.
